Compare Stocks

→ Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS (From Paradigm Press) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CGL iShares Gold Bullion ETF (CAD-Hedged)	C$19.00 +0.3%	C$17.28	C$14.58 ▼ C$19.41	C$931M	N/A	26,159 shs	51,566 shs
GBT Global Blood Therapeutics	$68.49	$68.47	$21.65 ▼ $73.02	$4.62B	0.45	2.07 million shs	74 shs

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CGL iShares Gold Bullion ETF (CAD-Hedged)	+0.32%	+0.16%	+10.34%	+16.92%	+17.94%
GBT Global Blood Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%

Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS (Ad)

You might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.

Click here to find out that this 8,788% cryptocurrency is.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CGL iShares Gold Bullion ETF (CAD-Hedged)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
GBT Global Blood Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CGL iShares Gold Bullion ETF (CAD-Hedged)	N/A	N/A	N/A	N/A
GBT Global Blood Therapeutics	N/A	N/A	N/A	N/A

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CGL iShares Gold Bullion ETF (CAD-Hedged)	N/A	N/A	N/A	N/A	N/A	N/A
GBT Global Blood Therapeutics	$194.75M	23.73	N/A	N/A	$3.05 per share	22.46

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CGL iShares Gold Bullion ETF (CAD-Hedged)	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
GBT Global Blood Therapeutics	-$303.09M	-$5.01	N/A	N/A	N/A	-137.30%	-170.37%	-39.24%	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CGL iShares Gold Bullion ETF (CAD-Hedged)	N/A	N/A	N/A	N/A	N/A
GBT Global Blood Therapeutics	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CGL iShares Gold Bullion ETF (CAD-Hedged)	N/A	N/A	N/A
GBT Global Blood Therapeutics	4.92	6.88	6.17

Ownership

Institutional Ownership

Company	Institutional Ownership
CGL iShares Gold Bullion ETF (CAD-Hedged)	N/A
GBT Global Blood Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
CGL iShares Gold Bullion ETF (CAD-Hedged)	N/A
GBT Global Blood Therapeutics	4.90%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
CGL iShares Gold Bullion ETF (CAD-Hedged)	N/A	49.00 million	N/A	Not Optionable
GBT Global Blood Therapeutics	457	67.48 million	64.17 million	Optionable

RCN, CGL, GBT, and GFT Headlines

Source	Headline
	Executive Profiles pharmexec.com - April 17 at 12:57 AM
	What the Amex GBT-CWT merger means for the travel industry travelweekly-asia.com - March 26 at 7:18 AM
	Amex GBT set to acquire CWT for USD 570mn travelbizmonitor.com - March 26 at 2:18 AM
	Amex GBT to purchase CWT for $871m travelweekly.com.au - March 26 at 2:18 AM
	Amex GBT to acquire rival CWT in $570m deal c-mw.net - March 25 at 4:18 PM
	Amex GBT acquires its competitor CWT fvw.de - March 25 at 9:25 AM
	Amex GBT buys rival CWT in $570m deal businesstravelnewseurope.com - March 25 at 9:25 AM
	Amex GBT to Acquire CWT for $570 Million skift.com - March 25 at 9:25 AM
	How Dr. Ted Love, a cardiologist turned biotech executive, sold his sickle cell company to Pfizer for $5.4B msn.com - March 22 at 4:27 PM
	GBT Warns Community of Fraudulent Message Circulation bossierpress.com - March 18 at 9:38 PM
	Global TV Trivia at Blood Brothers blogto.com - March 7 at 10:00 AM
	GBT set to reintroduce National Lottery dailynews.co.tz - March 7 at 10:00 AM
	Volume three of 100 GBT Clinical Cases unveiled dentistry.co.uk - February 16 at 9:56 AM
	Global Cystic Fibrosis Therapeutics Market Expected to Reach US$ 24.35 Billion by 2028 with a CAGR of 14.40% from 2022 medgadget.com - February 15 at 10:37 AM
	How Dr. Ted Love Sold Sickle Cell Company To Pfizer For $5.4 Billion forbes.com - February 5 at 3:22 PM
	Amex GBT addresses fraud with Expedia Group’s fraud prevention solution travelweek.ca - February 1 at 1:47 PM
	Global Wearable Blood Pressure Monitor Industry Set to Reach US$ 8 Billion by 2032, Fueled by Impressive 15%-16% CAGR \| Insights by FMI Analysis fmiblog.com - January 30 at 7:32 PM
	Answering the call for excellence with GBT dentistry.co.uk - January 23 at 6:19 AM
	Global Brain Tumor Drugs Industry is expected to reach a significant US$ 6.30 Billion by 2033, according to FMI’s forecast fmiblog.com - January 22 at 7:20 AM
	GBT Realty to Develop 42,000 SF Shopping Center in Kyle, Texas rebusinessonline.com - January 17 at 4:14 PM
	Better Therapeutics, Glooko partner on digital diabetes management massdevice.com - January 4 at 6:08 PM
	US biotech firm addresses critical gap in blood pressure management msn.com - December 27 at 8:55 PM
	Should we pay people for donating blood? bbc.com - December 20 at 1:36 PM
	Get on board with GBT for 2024 dentistry.co.uk - December 20 at 8:35 AM

New MarketBeat Followers Over Time

Top Headlines

3 Value Stocks Too Small For Buffett’s Portfolio
March 28, 2024 12:16 PM
View 3 Value Stocks Too Small For Buffett’s Portfolio
Foot Locker Builds Up Another Head of Steam; Gains Imminent
March 28, 2024 10:58 AM
View Foot Locker Builds Up Another Head of Steam; Gains Imminent
5 Stocks in the Current Bull Market with Upside to Come
April 5, 2024 10:14 AM
View 5 Stocks in the Current Bull Market with Upside to Come
5 Top-Rated Dividend Stocks With Double-Digit Upside
March 25, 2024 11:19 AM
View 5 Top-Rated Dividend Stocks With Double-Digit Upside
All In: Is MicroStrategy Overleveraging Its Future on Bitcoin?
March 26, 2024 6:05 AM
View All In: Is MicroStrategy Overleveraging Its Future on Bitcoin?

All Headlines

Company Descriptions

iShares Gold Bullion ETF (CAD-Hedged)

TSE:CGL

Global Blood Therapeutics

NASDAQ:GBT

Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD. In addition, the company is developing its lead product candidate inclacumab, novel human monoclonal antibody, which is in Phase III a clinical trial to reduce the incidence of painful vaso-occlusive crises, and resulting hospital admissions; and GBT601, a hemoglobin polymerization inhibitor that is in Phase I development. It has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD and beta thalassemia; and Sanofi S.A. to two early-stage research programs in SCD. Global Blood Therapeutics, Inc. was incorporated in 2011 and is headquartered in South San Francisco, California.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial